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A B S T R A C T
Background
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor that carries a 5-y
survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune response in
brain tumor patients have met with limited success, which is due to brain immune privilege,
tumor immune evasion, and a paucity of dendritic cells (DCs) within the central nervous system.
Herein we uncovered a novel pathway for the activation of an effective anti-GBM immune
response mediated by high-mobility-group box 1 (HMGB1), an alarmin protein released from
dying tumor cells, which acts as an endogenous ligand for Toll-like receptor 2 (TLR2) signaling
on bone marrow-derived GBM-infiltrating DCs.
Methods and Findings
Using a combined immunotherapy/conditional cytotoxic approach that utilizes adenoviral
vectors (Ad) expressing Fms-like tyrosine kinase 3 ligand (Flt3L) and thymidine kinase (TK)
delivered into the tumor mass, we demonstrated that CD4þ and CD8þ T cells were required for
tumor regression and immunological memory. Increased numbers of bone marrow-derived,
tumor-infiltrating myeloid DCs (mDCs) were observed in response to the therapy. Infiltration of
mDCs into the GBM, clonal expansion of antitumor T cells, and induction of an effective anti-
GBM immune response were TLR2 dependent. We then proceeded to identify the endogenous
ligand responsible for TLR2 signaling on tumor-infiltrating mDCs. We demonstrated that
HMGB1 was released from dying tumor cells, in response to Ad-TK (þ gancyclovir [GCV])
treatment. Increased levels of HMGB1 were also detected in the serum of tumor-bearing Ad-
Flt3L/Ad-TK (þGCV)-treated mice. Specific activation of TLR2 signaling was induced by
supernatants from Ad-TK (þGCV)-treated GBM cells; this activation was blocked by glycyrrhizin
(a specific HMGB1 inhibitor) or with antibodies to HMGB1. HMGB1 was also released from
melanoma, small cell lung carcinoma, and glioma cells treated with radiation or temozolomide.
Administration of either glycyrrhizin or anti-HMGB1 immunoglobulins to tumor-bearing Ad-
Flt3L and Ad-TK treated mice, abolished therapeutic efficacy, highlighting the critical role
played by HMGB1-mediated TLR2 signaling to elicit tumor regression. Therapeutic efficacy of
Ad-Flt3L and Ad-TK (þGCV) treatment was demonstrated in a second glioma model and in an
intracranial melanoma model with concomitant increases in the levels of circulating HMGB1.
Conclusions
Our data provide evidence for the molecular and cellular mechanisms that support the
rationale for the clinical implementation of antibrain cancer immunotherapies in combination
with tumor killing approaches in order to elicit effective antitumor immune responses, and
thus, will impact clinical neuro-oncology practice.
The Editors’ Summary of this article follows the references.
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Introduction
The systemic immune system can be ignorant of antigens
derived from tumors growing within the confines of the brain
parenchyma [1] owing to the paucity of professional antigen
presenting cells (APCs) and lymphatic drainage. Added to the
brain’s immune privilege [2], and tumor immune escape [3],
these factors pose clinically significant obstacles for successful
immunotherapy. The most aggressive intracranial primary
brain tumor is glioblastoma multiforme (GBM), which is
associated with 5% survival rates 5-y postdiagnosis, despite
advances in surgery, chemotherapy, and radiotherapy [4].
Novel experimental therapies that harness the power of the
patient’s immune system are being pursued to improve
therapeutic efficacy [5,6]. We postulated that the lack of
dendritic cells (DCs) within the brain parenchyma is central
to the failure of glioma cell killing approaches to stimulate a
strong adaptive antiglioma immune response. To this effect,
we developed a combined gene therapeutic approach aimed
at engineering the tumor microenvironment to induce the
migration into the tumor mass of APCs, combined with
tumor cell death to release tumor antigens. Our approach
consists of expressing Fms-like tyrosine kinase 3 ligand
(Flt3L), which induces DC infiltration into the brain
parenchyma [7], in combination with the conditional cyto-
toxic gene thymidine kinase (TK) [8].
Cell death can trigger antigen-specific immune responses
by releasing tumor antigens and signals that mediate
phagocytosis by DCs and also DC maturation. Tumor cell
death caused by radiation can induce DC-mediated cytotoxic
T-lymphocyte (CTL) responses and long-term antitumor
immunity [9]. These events can be triggered by the release
of endogenous Toll-like receptor (TLR) ligands from dying
cells [9] and can lead to either tolerance or auto-immunity
[10,11]. TLR signaling induces production of pro-inflamma-
tory cytokines and upregulation of costimulatory molecules,
which result in the activation of the adaptive immune system
[12]. In this context, it has recently been shown that TLR2 can
sense pancreatic b-cell death and contribute to the initiation
of auto-immune diabetes [13].
The development of many types of cancers has been linked
to chronic inflammation [14]. Inflammation is linked to
increased risks of tumorigenesis through alterations in tumor
cell survival, proliferation, and metastasis; modulation of
adaptive immune responses; increases in tumor angiogenesis;
and modifying the tumor microenvironment, thus affecting
the efficacy of antitumor therapies. Pro-inflammatory cyto-
kines (e.g., tumor necrosis factor-a [TNFa] and interleukin-6
[IL-6] secreted by macrophages and other innate immune
cells), as well as downstream signaling pathways (e.g., RAS and
myc) and the activities of transcription factors such as NF-jB
and STAT3, have all been linked to malignant transforma-
tion, and are also involved in tumor-related inflammation
[14–19]. While TLRs play an important role in detecting and
regulating the innate immune response to bacteria, viruses,
and/or parasites, TLRs are also necessary for the induction of
an adaptive immune response through the activation and
maturation of DCs and macrophages [20,21]. Herein we
demonstrate that codelivery of TK (þ systemic gancyclovir
[GCV]) to kill glioma cells and release putative endogenous
TLR ligands, with Flt3L to attract DCs to the brain, results in
a powerful, CD8þT cell-mediated systemic immune response
that elicits tumor regression and immunological memory.
TLR2 expression on bone marrow-derived DCs (BMDC) was
necessary to stimulate a systemic antiglioma immune re-
sponse. Activation of TLR2 signaling was essential for two key
stages in priming immune responses against brain tumor
antigen: (1) the migration of peripheral DC into the brain
tumor, and (2) the subsequent activation of DC and
stimulation of tumor antigen specific T cell clonal expansion.
We identified high-mobility-group box 1 (HMGB1) as an
endogenous TLR2 agonist that was released from dying
tumor cells, both in vitro and in vivo in response to several
tumor cell killing approaches, i.e., adenoviral vector (Ad)-TK
(þGCV), radiation, and temozolomide. Blocking HMGB1
activity in vivo using glycyrrhizin or specific anti-HMGB1
neutralizing antibodies, inhibited Flt3L/TK-induced brain
tumor regression. Thus, tumor-derived HMGB1 elicits en-
dogenous TLR2 signaling and initiates a CD8þ T cell-
dependent anti-GBM immune response.
The clinical impact of these data is highlighted by the
recent description of subpopulations of human cancer
patients containing SNPs or microsatellite polymorphisms
in TLR2, or the heterodimeric receptors TLR1 and TLR6 [22–
26]. Patients that harbor mutations in the TLR2 signaling
pathway have significantly poorer clinical outcome and more
rapid progression of gastric, colorectal, lymphoma, and
prostate cancer than patients with normal TLR2 signaling
components [22–26]. It is thus likely that our conclusions
related to antiglioma immune responses may be extended to
enhancing immune responses against other cancers. Further,
our data also provide support to the implementation of
antibrain cancer immunotherapies in combination with
tumor killing approaches in the clinical setting.
Methods
Ads, Cell Lines, Plasmids, and Reagents
We used first generation, recombinant Ads (serotype 5)
expressing Herpes Simplex Virus Type I-TK (Ad-TK) [8,27],
Flt3L (Ad-Flt3L) [7], and an Ad vector with no transgene
(Ad0) in this study [8]. The methods for adenoviral
generation, purification, characterization, and scale-up have
been previously described by our lab [28]. GL26 and GL261
were obtained from NCI; LLc1 and B16-F10 cells were
obtained from ATCC; and HEK-293 cells were obtained from
Microbix. CNS1 were a gift from W. Hickey (Department of
Pathology, Dartmouth Medical Center, Lebanon, New Hamp-
shire, USA) and DSL6A were a gift from D. Longnecker
(Department of Pathology, Dartmouth Medical Center).
HEK293 cells were cultured in MEM supplemented with
nonessential amino acids, 1% Pen-Strep, 1% L-Glutamine (all
from CellGro), and 10% FCS (Omega Scientific). All other cell
lines were grown in DMEM culture media (CellGro) supple-
mented with 10% FCS and 1% Pen-Strep and passaged
routinely every 2–3 d. pCMV-TLR2 and pCMV-TLR4 were a
gift from Mike Roth [29] and pEF1a-MD2 was a gift from
Kensuke Miyake [30]. pGL3-NFjB and pRL-TK were pur-
chased from Promega. PAM3CSK4 and LPS were purchased
from Invivogen. Dual Luciferase assay was purchased from
Promega. IL6 and TNFa ELISA kits were purchased from
Ebioscience. The fluorescent-conjugated immunoglobulins
CD3-PE, CD3-PerCP, CD4-PerCP, CD8a-FITC, CD8a-PE,
CD11c-PE, CD45-PE, CD45-PerCP, and MHC II-FITC were
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all purchased from BD Biosciences. r-PE labeled Trp2180–188
loaded MHC I tetramers were obtained from Beckman
Coulter Inc. and recombinant human IL-2 (Proleukin) was
purchased from Novartis Pharmaceuticals Corporation. The
LPS detection kit QCL-1000 Chromogenic LAL Endpoint
assay was purchased from Lonza and EndoFree Plasmid Maxi
kit was purchased from Qiagen. Temozolomide (Temodar)
was obtained from Schering Corporation and provided by the
CSMC Pharmacy.
Transgenic Mouse Models and Mixed Chimeric Mice
GL26 cells did not contain Y chromosomal sequences so
were derived from a primary tumor in a female C57BL/6
mouse (Figure S1). Consequently, female C57BL/6 mice were
used throughout this study. MyD88/ and TLR4/mice have
been previously described [31] and were kindly provided by S.
Akira (Osaka University, Osaka, Japan). We backcrossed
MyD88/ for ten generations and TLR4/ for six generations
into the C57BL/6J strain to generate a homogenous popula-
tion. Wild-type (WT) C57BL/6J, Balb(c), TLR2/ (B6.129-
Tlr2tm1Kir/J stock number 004650), CD4/ (B6.129S2-Cd4tm1Mak/
J stock number 002663), CD8/ (B6.129S2-Cd8atm1Mak/J stock
number 002665), Rag1/ (B6.129S7-Rag1tm1Mom/J stock num-
ber 002216), and green fluorescent protein (GFP)þ/þ (C57BL/6-
Tg(UBC-GFP)30Scha/J stock number 004353) mice, all on a
C57BL/6J background were purchased from Jackson Labo-
ratories. Two sets of chimeric mice were used in this study.
We generated chimeric mice using WT C57BL/6 mice and
GFPþ/þ mice (Figure S2) to assess the origin of tumor-
infiltrating DC. We also made chimeric mice using WT
C57BL/6 mice and TLR2/ mice to assess the role of TLR2
signaling on bone marrow- and microglia-derived cells. To
establish mixed chimeric mice, we first irradiated recipient
mice (7 Gy) using an irradiator with a 137Cs source and
allowed the mice to recover for 4 h in their home cages. We
humanely killed adult donor mice (4–6 wk old by CO2
asphyxia and cervical dislocation) and extracted bone
marrow from the long bones. Recipient mice were anaes-
thetized the same day with an IP injection of ketamine (75 mg/
kg) and medetomidine (0.5 mg/kg), and placed under a heat
lamp for 5 min. 107 bone marrow cells in 100 ll were then
transferred via tail vein injection into recipient irradiated
mice using a tuberculin syringe with a 31-gauge needle.
Atipamazole (IP) was used to recover mice from anesthesia.
Bone marrow in the recipients was allowed to reconstitute for
10 wk prior to tumor implantation and subsequent treat-
ment. We established four chimeric mouse lines: WT mice
with TLR2/ bone marrow; TLR2/ mice with WT bone
marrow; WT mice with GFPþ bone marrow; and GFPþ mice
with WT bone marrow. Generally, repopulation of irradiated
mice is not 100% efficient [32], and GFP expression is not
uniformly expressed in all cells [33], therefore data need to be
compared and normalized to the percentage of green
immune cells present in normal GFPþ/þ mice.
Glioma Model
To establish a syngeneic intracranial brain tumor model,
we used GL26 cells [34,35] derived from a female C57BL/6
mouse intracranial neoplasm (Figure S1). Other intracranial
brain tumor models tested in C57Bl/6 mice were: GL261 cells
(glioma) or B16-F10 cells (melanoma). Female mice (6–12 wk)
were anesthetized with an IP injection of ketamine (75 mg/kg)
and medetomidine (0.5 mg/kg), placed in a stereotactic
apparatus modified for mice, and a hole was drilled in the
skull. 23 104 GL26, 23 104 GL261 cells [36], or 13 103 B16-
F10 cells [37] in 0.5 ll PBS were injected unilaterally into the
right striatum (þ0.5 mm AP,þ2.2 mm ML,3.0 mm DV from
bregma) using a 5-ll Hamilton syringe with a 33-gauge
needle. The needle was left in place for 3 min prior to
removal to allow tumor cells to settle at the injection site.
Mice were resuscitated using atipamazole (IP) and adminis-
tered buprinex (SQ) as an analgesic. 17 d after tumor
implantation and using the same stereotactic coordinates,
mice received an intratumoral injection of either 13 108 IU
Ad0, 53 107 IU Ad-Flt3Lþ 53 107 IU Ad0, 53 107 IU Ad-TK
þ 53 107 IU Ad0, or 53 107 IU Ad-Flt3Lþ 53 107 IU Ad-TK
in 1 ll saline. Alternatively, mice were injected with 1 ll saline
as a control. Mice treated with Ad-TK also received 25 lg/kg
GCV (IP, Roche) twice daily for 7 d starting the day after
vector injection. To perform tumor cell rechallenge into the
contralateral brain hemisphere, mice were anaesthetized as
described above, a hole was drilled in the skull, and 2 3 104
GL26 cells in 0.5 ll PBS were injected at the following
coordinates (þ0.5 mm AP, 2.2 mm ML, 3.0 mm DV from
bregma). All animal experiments were performed after prior
approval by the Institutional Animal Care and Use Commit-
tee at Cedars Sinai Medical Center and conformed to the
policies and procedures of the Comparative Medicine
Department. Mice used in this study were monitored for
signs of moribund behavior and euthanized when their health
status reached criteria established by the guidelines of the
IACUC. Animals were humanely killed by terminal perfusion
with oxygenated, heparinized Tyrode’s solution (132 mM
NaCl, 1.8 mM CaCl2, 0.32 mM NaH2PO4, 5.56 mM glucose,
11.6 mM NaHCO3, and 2.68 mM KCl).
IFNc ELISPOT
106 splenocytes were purified from tumor-bearing mice
(WT C57BL/6 or TLR2/) treated with intratumoral injec-
tions of saline or Flt3L and TK. Splenocytes were next
prestimulated on a monolayer of fixed GL26 cells (1% PFA
for 15 min at RT) in the presence of 10 U/ml IL-2 for 14 d.
Fresh IL-2 (at the same concentration) was added every
fourth day. Myeloid DCs (mDC) (CD11cþ, CD45þ, MHC II þ)
were stained as described in the flow cytometry section and
then purified from naı¨ve WT C57BL/6 mouse splenocytes by
cell sorting (MoFlow, DAKO). To prepare cellular extracts, 1
3 106 GL26 cells or LLc1 cells were first heat shocked in a 25-
cm2 tissue culture flask (42 8C, 1 h), allowed to recover (37 8C,
2 h), and then freeze thawed by transferring frozen from
liquid N2 into 37 8C three times. Cell membranes and other
insoluble debris were then removed by centrifugation (12,000
3 g, 15 min, 4 8C), and protein concentration was determined
by BCA assay (Peirce). Purified mDC were loaded with tumor
cell extracts by culturing in 2 ml media (in a six-well plate)
containing 100 lg/ml GL26 cell extract or 100 lg/ml LLc1 cell
extract for 12 h at 37 8C and then were fixed in 1% PFA (in
PBS) for 5 min at RT before washing three times with PBS. 13
105 stimulator cells (mDC loaded with GL26 or LLc1 cell
extract) were incubated with 1 3 105 responder cells
(prestimulated T cells) in triplicate for 48 h on 96-well plates
coated with mouse anti-IFNc capture antibody (R&D Systems
mouse IFNc ELISPOT Development kit). IFNc spots were
developed with an anti-mouse IFNc development antibody as
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recommended by the manufacturer’s detailed instructions
(R&D Systems mouse IFNc ELISPOT Development kit).
Concanavalin A (1 lg/ml, 4 h) (Sigma) stimulation of WT
and TLR2/ splenocytes was used as a control in lieu of
stimulation with tumor extract pulsed DC.
Reverse Transcriptase-PCR
RNA was extracted from GL26 cells using RNABee reagent
(Tel-test). A reverse transcriptase reaction was set up using
0.5 lg RNA and oligo-dT primer with MMLV Reverse
Transcriptase (Promega) (75 8C, 10 min; 42 8C, 1 h; 4 8C, ‘).
Primers specific for nucleotides 520 to 951 of mouse GAPDH
coding sequence (forward 59-ACC ACA GTC CAT GCC ATC
AC-39; reverse 59-TCC ACC ACC CTG TTG CTG TA-39)
(Operon) or nucleotide 676 to 1,176 of mouse Trp2 coding
sequence (forward 59-TGG CTG GAA AGA GAA CTC CA-39;
reverse 59-GTA AAA GAG TGG AGG ACC ACA-39) (Operon)
were subsequently used to amplify target sequences from the
cDNA using PCR (Taq, Promega, 95 8C, 1 min; 55 8C, 1 min; 72
8C, 1 min). DNA bands were separated using agarose gel
electrophoresis (IscBioExpress, 1% w/v) and visualized using a
gel documentation system (Alpha Innotech Corporation).
Isolation of Immune Cells
Splenocytes were harvested and red blood cells were
removed by incubating in 3 ml ACK solution (0.15 mM
NH4Cl, 10 mM KHCO3, and 0.1 mM sodium EDTA at [pH
7.2]) for 3 min. Splenocytes were then washed in RPMI media
(containing 10% FBS, 1% PS, 1% L-Gln). Cervical (draining)
lymph nodes (dLNs) were homogenized using a Tenbroeck
homogenizer. Tumor-infiltrating immune cells were purified
by perfusing tumor-bearing mice with 100 ml (oxygenated)
heparinized Tyrode’s Solution 7 d after intratumoral in-
jection of Ad-Flt3L and Ad-TK, or Ad0 or saline. Brains were
removed from the skull and carefully separated from the
meninges with scissors. The tumor was carefully dissected
with a scalpel blade and removed avoiding the ventricles. The
tumor tissue was diced with a razor blade before homogeniz-
ing in RPMI medium (CellGro) using a glass Tenbroeck
homogenizer (Kontes). Mononuclear cells were purified from
brain tissue by centrifugation (6003 g) through a Percol step
gradient (70% to 30% Percol in PBS) for 20 min in 15-ml
falcon tubes (GE Healthcare); mononuclear cells migrate to
the interface between 30% and 70% Percol. The mono-
nuclear cells on the interphase were removed into 10 ml fresh
media, washed, and counted using Trypan blue.
Antibodies, Cell Staining, and Flow Cytometry
Immune cells were labeled with antibodies in cell surface
staining buffer (0.1M PBS, w/o Caþþ, Mgþþ, with 1% FBS, 0.1%
sodium azide) for analysis by flow cytometry using a FACScan
flow cytometer (Beckton Dickenson). To analyze mDC
(CD11cþ MHC IIþ CD45þ), we stained with CD11c-PE, MHC
II-FITC, and CD45-PerCP. To determine the origin of DC in
the tumors using GFP chimeric mice, we isolated tumor-
infiltrating immune cells as described above and stained with
CD11c-PE and CD45-PerCP. Microglia (from the chimeric
mice) (CD11bþ CD45int) were stained with CD11b-PE and
CD45-PerCP. GFPþ and GFP cells were detected on the FL-1
channel of the flow cytometer. Other immune cells analyzed
during this study (unpublished data) were macrophages
(CD11bþMHC IIþ CD45hi), CD4þ T lymphocytes (CD3þ CD4þ
CD8a), CD8aþ T lymphocytes (CD3þ CD4 CD8aþ), NK cells
(CD3CD161þCD45þ), NK-T cells (CD3þCD161þCD45þ), and
B lymphocytes (CD3 CD19þ CD45þ). Antibodies were pur-
chased from BD Biosciences. Mouse anti-HMGB1 was pur-
chased from Sigma and HRP-conjugated antibodies (rabbit
anti-mouse and goat anti-rabbit) were purchased from Dako.
T Cell Proliferation Assay
Splenocytes were purified from tumor-bearing WT C57BL/
6 mice and from TLR2/ mice previously treated with
intracranial injections of Ad-Flt3L þ Ad-TK or with saline 7
d earlier. Red blood cells were removed using ACK as
outlined above. 107 splenocytes were stained with 4 lM CFSE
(Invitrogen) for 30 min at RT in complete RPMI media.
During cell division, CFSE is equally distributed amongst
daughter cells, with each daughter cell inheriting half the
original CFSE. Therefore, each daughter cell will only retain
half the original fluorescence while cells that do not divide
will not lose any fluorescence. Thus, the sequential halving of
the mean CFSE fluorescence can determine the number of
cell divisions each cell has undergone. Cells were washed with
RPMI media and incubated with or without 1 lg/ml Trp2180–188
peptide (SVYDFFVWL) for 5 d. Cells were stained with CD3-
PE and CD4-PerCP and T cell proliferation was analyzed by
flow cytometry. The total number of T cells that had less than
one-fourth their original fluorescence (i.e., had divided two
or more times) were quantified using flow cytometry and
expressed as a percentage of the total T cell population. Data
were analyzed using DAKO Summit 4.1.1 software.
Proliferation of T Cells in Response to IL-2
Tumor-bearing WT (C57BL/6) or TLR2/ mice were
treated 17 d after tumor cell implantation with intratumoral
injections saline, or with Ad0, Ad-Flt3LþAd0, Ad-TKþAd0,
or Ad-Flt3L þ Ad-TK as outlined above. T cells were labeled
with CD3-PerCP and purified (by cell sorting) from the
draining (cervical) LN 7 d after treatment. T cells were then
labeled with 4 lM CFSE (Invitrogen) for 30 min (107 cells/ml)
at 37 8C before washing twice in 10 ml RPMI media. They
were then cultured in 96-well plates (100,000 cells per well) in
200 ll X-VIVO (Cambrex) for 5 d in the presence of 10 U/ml
recombinant human IL-2 at 37 8C. T cells were then stained
with CD3-PE and the total number of T cells that had less
than one-fourth their original fluorescence (i.e., had divided
two or more times) were quantified using flow cytometry and
expressed as a percentage of the total T cell population.
Determining the Origin of Tumor-Infiltrating DC
Chimeric mice were used to assess the origin of CD11cþ
mDC infiltrating into the tumor. We established mixed
chimeric mice using the principle that microglial cells are
relatively radio resistant whereas bone marrow is radio
sensitive. WT and GFPþ/þ mice were used as controls.
Chimeras were as follows: WT mice were irradiated and
adoptively transferred with GFPþ/þ bone marrow; or GFPþ/þ
mice were irradiated and adoptively transferred with WT
bone marrow. GL26 cells were implanted in these mice 10 wk
after irradiation and treated 17 d later with Ad-Flt3L and Ad-
TK. 7 d after the treatment tumor infiltrating immune cells
and splenocytes were isolated; flow cytometry was performed
to detect total GFPþ splenocytes, GFPþ tumor-infiltrating
microglia, or GFPþ tumor-infiltrating mDC. In GFPþ/þ mice,
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83% of splenocytes, 55% of microglia, and 29% of mDC were
observed to be GFPþ. In WT mice 2% of splenocytes, 0.05% of
microglia, and 0% of mDC were observed to be GFPþ.
Normalized values of %GFPþ immune cells encountered
within spleens of the chimeric mice were calculated as
follows: Normalized %GFPþ immune cells in spleens of WT
mice adoptively transferred with GFPþ/þ bone marrow ¼
(%GFPþ splenocytes: 87%  2%)/(83%  2%) ¼ 104%.
Normalized %GFPþ immune cells in spleens of GFPþ/þ mice
adoptively transferred with WT bone marrow ¼ (%GFPþ
splenocytes: 14%  2%)/(83%  2%) ¼ 15%. The equation
utilized to normalize the value of %GFPþ microglia encoun-
tered within tumors of chimeric mice was as follows:
Normalized %GFPþ microglia infiltrating the tumors of WT
mice adoptively transferred with GFPþ/þ bone marrow ¼ (%
intratumoral GFPþ microglia in the tumor: 11%  0.05%)/
(55%  0.05%) ¼ 20%. Normalized %GFPþ microglia
infiltrating the tumors of GFPþ/þmice adoptively transferred
with WT bone marrow¼ (% intratumoral GFPþ microglia in
the tumor: 53%0.05%)/(55%0.05%)¼98%. The equation
utilized to normalize the value of %GFPþ mDC encountered
within tumors of the chimeric mice was as follows: Normal-
ized %GFPþ mDC infiltrating the tumors of WT mice
adoptively transferred with GFPþ/þ bone marrow ¼ (%
intratumoral GFPþ mDC in the tumor: 22%  0%)/(29% 
0%)¼ 76%. Normalized %GFPþmDC infiltrating the tumors
of GFPþ/þmice adoptively transferred with WT bone marrow
¼ (% intratumoral GFPþmDC in the tumor: 2%0%)/(29%
0%) ¼ 7%.
Identifying Whether TLR2 Expression Is Necessary on Bone
Marrow- or Microglia-Derived Cells
Two bone marrow chimeric mouse groups were generated
using TLR2/ and WT donors and recipients respectively.
Mice were allowed to regenerate their bone marrow for 10 wk
before intracranial implantation of GL26 tumor cells as
described above. Tumors were allowed to grow for 17 d
before treatment with 53107 IU Ad-Flt3L and 53107 IU Ad-
TK (þGCV). Mice were monitored daily and euthanized as
described above when moribund. A Mantel log-rank test was
used to calculate significant differences between groups.
Culture of DC from Bone Marrow for Subsequent
Intratumoral Injection
BMDC were generated as described previously [38] with
modifications. Mice were humanely killed by CO2 asphyx-
iation followed by cervical dislocation. Bone marrow was
extracted from the long bones and a single cell suspension of
bone marrow was created by pipetting up and down with a
P1000 pipette. BMDC were cultured from hematopoietic
stem cell precursors by supplementing the media with 10 ng/
ml Flt3L conditioned media (generated by infecting COS-7
cells with Ad-Flt3L). Media was replaced with 10 ng/ml fresh
Flt3L conditioned media every 2–3 d. By day 7, .90% of
loosely adherent cells were CD11cþ (unpublished data) as
determined by flow cytometry. Loosely adherent cells were
removed and used for subsequent intratumoral injection and
phagocytosis/activation/antigen presentation assays.
Preparation of Apoptotic and Necrotic Cell Extracts
Necrotic cell extracts were made from GL26 cells (or other
tumor cell lines) as outlined in the IFNc ELISPOT protocol.
Cell extracts were used fresh or were frozen at 80 8C for
future use. Apoptotic GL26 cells were generated by infecting
GL26 cells (in a T25 flask, 0.53106 cells per flask) with Ad-TK
(MOI 1,000 IU/cell). After 24 h, media was replaced with fresh
media containing 25 lM GCV. A final concentration of 10 lM
GCV was added fresh to the cells every day, until the third or
fourth day when we detected .80% apoptosis using Annexin
V-FITC (Bender MedSystems) and Propidium Iodide (Sigma)
staining followed by flow cytometry analysis. Cells that were
positive for Annexin V-FITC were quantified to determine
the percentage apoptosis.
Assessment of Apoptosis In Vitro
The pattern of DNA cleavage was analyzed by DNA ladder
electrophoresis. Briefly, GL26 cells were infected (MOI 1,000
IU/cell) with Ad-TK (þGCV), Ad-TK, Ad-0, or mock infected.
72 or 96 h postinfection DNA was isolated from 53 106 13
107 cells using an Apoptotic DNA Ladder kit (Roche
Diagnostics). DNA was subjected to electrophoresis on 2%
agarose gel for 90 min at 45 V. DNA was stained with
ethidium bromide.
Elimination of Brain Tumors with Intratumoral Delivery of
BMDC Containing GL26 Cell Extracts
2 3 104 GL26 cells were implanted into the striatum of
C57BL/6 mice as outlined before. BMDC were cultured from
bone marrow of WT C57BL/6 mice and TLR2/ mice in IL4
and GM-CSF as described previously. After 7 d, 106 WT and
TLR2/ BMDC were loaded with 100 lg/ml GL26 cell extract
in 2 ml RPMI media for 4 h at 37 8C before centrifuging,
resuspending at 25,000 cells/ll in PBS, and injecting directly
into the 7-d intracranial GL26 brain tumor. Mice were
monitored and euthanized as described earlier.
Tumor Antigen Phagocytosis Assay
GL26 cells were labeled with the fluorescent dye PKH67
(Sigma) as follows; Cells were resuspended at 13 107 cells/ml
in 1 ml diluent C from the PKH67 Green Fluorescent Cell
Linker kit (Sigma) in a 15-ml conical tube before addition of 2
3 106 M PKH67 dye while vortexing rapidly for 5 s. Cells
were incubated for 5 min at RT before adding 2 ml of 1%
BSA solution (Sigma) in Dulbecco’s PBS (CellGro) to stop any
further labeling of cells. 4 ml RPMI complete media was
added to the sample and cells were washed four times with 10
ml RPMI complete media before resuspending in 1 ml PBS.
Cell extracts were next prepared by rapidly freeze thawing
three times as described above. 0.1 mg/ml of PKH67 labeled
GL26 cell extract was added to 13106 WT C57BL/6 BMDC or
13 106 TLR2/ BMDC, previously cultured for 7 d with IL4
(10 ng/ml) and GM-CSF (10 ng/ml). BMDC were incubated 4
8C or at 37 8C for 16 h and washed with 1 ml FACS staining
buffer before staining with CD11c-PE and CD45-PerCP as
described above and analyzed by flow cytometry using a
FACScan flow cytometer (Beckton Dickenson). The time
course analysis was performed between 0 to 6 h.
ELISA
HMGB1 expression was determined in mouse serum using
a specific anti-HMGB1 ELISA (Shino Test Corporation)
following the manufacturers protocol. Briefly, 100 ll sample
diluent was added to each well. Next, 10 ll of mouse serum
was added to each well and incubated at 37 8C for 24 h. Wells
were washed five times with wash buffer and incubated for 2 h
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at 25 8C with 100 ll of POD-conjugate solution. Wells were
washed a further five times in wash buffer and incubated for
30 min at room temperature with substrate solution. The
reaction was stopped by adding 100 ll of stop solution to
each well and the absorbance was read at 450 nm (the
background was substracted by measuring absorbance at 570
nm). Expression of mouse TNFa and mouse IL6 from BMDC
stimulated with PAM3CSK4 or necrotic/apoptotic GL26 cell
extracts was determined using ELISA following the manu-
facturer’s protocol exactly (Ebioscience). Briefly, DC previ-
ously cultured from bone marrow for 7 d in GM-CSF and IL4
were cultured in 96-well plates at 50,000 cells per well in 200
ll of RPMIþ10% FBS. 0.1 mg/ml GL26 cell extracts or 100 ng/
ml PAM3CSK4 were added to BMDC in culture and cells were
incubated for 24 h (at 37 8C). Media was removed and 50 ll
was used to detect either TNFa or IL6 by ELISA. To do so, 96-
well ELISA plates (Corning Costar 9018) were coated with the
appropriate capture antibody diluted in coating buffer
overnight at 4 8C. The coated plates were washed the next
day by aspirating and washing five times with wash buffer (13
PBSþ 0.05% Tween-20), blocked with assay diluent at RT for
1 h, and then washed five times with wash buffer. Samples
were diluted 1:2 in assay diluent and added to the plate with
known concentrations of TNFa and IL6 standards. Plates
were incubated overnight at 4 8C, before washing five times
with wash buffer. The TNFa or IL6 detection antibody
(supplied with the kit) was added for 1 h at RT before washing
five times and adding Avidin-HRP (supplied with the kit).
Wells were incubated for 30 min and washed seven times.
Substrate solution (TMB) (supplied with the kit) was added
for 30 min at RT and the reaction was stopped by the
addition of 2N H2SO4 (supplied with the kit). Wells were read
on a 96-well plate reader (Spectramax Plus, Molecular
Devices) at 450 nm and also then at 570 nm to subtract
background absorbance.
Allogeneic MLR
BMDC (Kb haplotype) were cultured from WT and TLR2/
bone marrow for 7 d as described previously, then activated
by incubating with 100 lg/ml GL26 cell extract for 24 h (at 37
8C). CD4 and CD8 T cells were isolated using a magnetic
activated cell sorter (MACS) from total splenocytes of Balb(c)
mice (Kd haplotype) using mouse CD4 (L3T4) and CD8a (Ly-2)
magnetic beads (Miltenyi Biotec). Total splenocytes were
washed once with 15 ml MACS staining buffer (0.5% BSA in
PBS with 2 mM EDTA, degassed), centrifuged for 15 min at
800g, and labeled with CD4 and CD8a magnetic beads (1:10)
in MACS staining buffer (107 cells/100 ll) for 15 min at 4 8C.
Cells were then washed once more in MACS staining buffer
and CD4þ and CD8aþ cells were positively selected using
MACS LS columns in a Vario MACS sorter according to
manufacturer’s recommended protocol. 25,000 total res-
ponders (T cells, 1:1 ratio CD4:CD8a) were incubated in v-
bottom 96-well plates (Corning) with increasing numbers
(none, 1:100, 1:30, and 1:10) of allogeneic BMDCs (stimula-
tors) in RPMI 1640 media supplemented with 10% FCS, 1%
Pen-Strep for 3 d (at 37 8C). 1 3 BrdU (Exalpha Biologicals
Inc.) was added to the media for the final 24 h and BrdU
incorporation into nascent DNA strands was assessed by
ELISA (BrdU Cell Proliferation Assay). Relative proliferation
of T cells compared with T cell proliferation in the absence of
any stimulators was plotted for increasing ratios of stimula-
tors (BMDC) compared with responders (T cells).
Syngeneic MLR
WT and TLR2/ BMDC were differentiated as described
above and loaded with 0.1 mg/ml GL26 cell extracts for 4 h.
CD4þ and CD8aþ T cells were purified from total splenocytes
from tumor-bearing mice 7 d after treatment with Flt3L and
TK as described above. T cells were stimulated for 14 d with
BMDC (1:10 ratio BMDC-GL26:T cell) loaded with GL26
tumor cell extract in the presence of 10 U/ml IL-2 to select for
and expand tumor antigen specific T cell clones. Fresh
BMDC-GL26 (1:10 ratio to T cells) were added after 7 d and
fresh IL-2 (10 U/ml) was added every 4 d. On day 14, 13 105 T
cells (responders) were incubated per well in v-bottom 96-well
plates (Corning) with increasing numbers (none, 1:100, and
1:30) of syngeneic BMDCs loaded with 0.1 mg/ml GL26 tumor
antigen 24 h earlier (stimulators) in 200 ll RPMI 1640 media
(CellGro) supplemented with 10% FCS, 1% Pen-Strep for 3 d.
13BrdU was added to the media for the final 24 h and BrdU
incorporation into nascent DNA strands was assessed by
ELISA (Exalpha Biologics Inc.) following the manufacturers
protocol exactly.
In Vitro TLR Activation Assay
An NFjB reporter plasmid driving firefly luciferase
expression was used to determine signal transduction from
TLR expressing HEK 293 cells as follows; HEK 293 cells were
plated in 24-well plates at 50,000 cells per well and were
transfected the next day with 50 ng pGL3-NFjB (Firefly
Luciferase expressing reporter plasmid under the control of a
NFjB response element), 5 ng pRL-TK (Renilla Luciferase
expressing normalizing plasmid), and either 60 ng pCMV-
TLR2 or 30 ng each of pCMV-TLR4 and pEF1a-MD2 using 1:2
ratio of DNA to JetPEI (Polyplus). All plasmids were purified
with Endo-Free Maxiprep kits (Qiagen) and confirmed free of
LPS using an LPS assay (Lonza). Media was removed 24 h later
and replaced with fresh complete MEM. Cells were then
stimulated for 6 h with 0.1 mg/ml GL26 cell lysate, GL26 cells
treated with Ad-TK (þGCV), 100 ng/ml PAM3CSK4 (Inviv-
ogen), 1 lg/ml LPS (Invivogen), or an equal volume of
endotoxin free medium as a negative control. TLR2-express-
ing 293 cells were incubated with the above stimuli in the
presence or absence of glycyrrhizin (at a final concentration
of 100 lM). Firefly activity was determined from cell lysates
using a Dual Luciferase Reporter Assay kit (Promega) exactly
as outlined by the manufacturers recommended protocol.
Renilla Luciferase activity was also determined to normalize
the activity of NFjB in each sample. Data are expressed as
relative light units (RLU) by calculating the value of (FFLuc-
Background)/(rLuc-Background).
Generating HMGB1-Depleting Antibodies
Antibodies were custom generated by New England
Peptides and raised in New Zealand White rabbits against
the N-terminal 11 amino acids of HMGB1 (MGKGDPKKPRG)
(see Figure S3) [39]. The peptide was conjugated to KLH using
a C-terminal cysteine residue. Rabbits were immunized with
the KLH-conjugated peptide in complete Freunds adjuvant
and then boosted twice with the KLH-coupled peptide in
incomplete Freunds adjuvant 14 d and 28 d after initial
immunization. Serum was taken on day 35 and analyzed by
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ELISA (with a minimum of a 1:15,000 ELISA titer) and
western blot (of GL26 cell extracts as described below). Serum
was aliquoted and stored at 80 8C. IgG immunoglobulins
were affinity purified using Protein G spin columns (Montage
PROSEP-G, GE Healthcare) as described in the manufac-
turers technical datasheet. Briefly, the PROSEP-G column was
pre-equilibrated with 10 ml binding buffer A by centrifuging
at 5003 g for 5 min before loading 5 ml antibody (diluted 1:1
binding buffer A) and centrifuging at 150g for 20 min. The
column was washed with 20 ml binding buffer A for 5 min to
remove unbound contaminants and the antibody was eluted
with 10 ml elution buffer B2 into 1.3 ml neutralizing buffer C.
The affinity purified anti-HMGB1 antibody was used the same
day in depletion studies (neat, 1 mg in 600 ll per mouse).
SDS-PAGE and Western Blot Analysis of HMGB1 and
b-Actin
1 ml media was removed from GL26 cells treated with Ad-
TK and GCV 24, 48, and 72 h earlier (or mock infected
controls) and centrifuged at 12,0003 g for 20 min to remove
cell debris. We diluted the supernatants with SDS-PAGE
loading buffer (100 mM Tris [pH 6.8], 20% v/v glycerol, 4% w/
v SDS, 0.02% w/v bromophenol blue) with 50 mM DTT and
boiled at 95 8C for 5 min. Denatured samples were loaded
onto a 12% SDS-polyAcrylamide gel with 5% stacking gel.
Electrophoresis of the samples was conducted at 130 V for 1.5
h and proteins were then transferred at 90 V for 1 h by wet
transfer to a nitrocellulose membrane (GE Healthcare). The
membrane was blocked with 5% milk in TBS þ 0.05%
Tween20 (Blotto) at RT for 1 h, then stained with either
mouse anti-HMGB1 (Sigma H9537 1:1,000), rabbit anti-
HMGB1 (custom, 1:1,000), or with mouse anti-b-Actin (Sigma
A1978 1:1,000) for 1 h at RT. Membranes were washed three
times in TBS with 0.05% Tween20 and HRP-conjugated
rabbit anti-mouse immunoglobulins (DAKO P0260) were
incubated in 5% blotto to detect HMGB1. Immunoreactivity
was visualized by exposing Western blots to KODAK X-
OMAT LS film and developed on a KODAK INDUSTREX
M35 Processor. The density of immunostaining in each lane
was determined using Adobe Photoshop 6.0.
Inhibition of HMGB1 In Vivo with Glycyrrhizin and
Depleting Anti-HMGB1 Antibodies
WT mice were challenged with 20,000 GL26 cells delivered
into the striatum as described above and treated with Ad-
Flt3L and Ad-TK (þGCV) or with an equal volume of saline
(control) 17 d later. Glycyrrhizin (Calbiochem), was diluted
fresh to a concentration of 100 mg/ml in 50 mM NaOH at 37
8C and pH was adjusted to pH 7.4 using 1M Tris-HCl. The
solution was then filtered through a 0.22 lm syringe pump
filter and 100 ll (10 mg glycyrrhizin) were administered to
tumor-bearing mice by IP injection [40]. We administered
glycyrrhizin 2, 5, and 10 d after injection of Ad-Flt3L and Ad-
TK or saline. HMGB1-depleting immunoglobulins (custom
antibody generated by New England Peptides) or rabbit IgG
isotype control immunoglobulins (Sigma) were affinity
purified (Montage, Millipore), tested for LPS contamination
(Lonza), and injected in mice on day 19, 22, and 27 after
tumor cell implantation (600 lg/mouse IP). Mice were
monitored daily and euthanized when moribund. A Mantel
log-rank test was used to determine significant differences in
Kaplan-Meier survival curves.
Treatment of Tumor Cell Lines with Ad-TK (þGCV),
Radiation, or Chemotherapy
GL26, LLc1, GL261, or B16-F10 cells were seeded at a
density of 2.5 3 105 cells per flask. Cells were then treated
with Ad-TK (þGCV), subjected to radiation, or treated with
chemotherapy (temozolomide). Cells were infected with Ad-
TK and treated with GCV as described above. As controls
cells were infected with Ad0 at an MOI¼ 500. Cells were also
mock infected as a control. 48 h later, supernatant was
collected to assess HMGB1 release by Western blot or
HMGB1 specific ELISA. To assess the effects of radiation on
HMGB1 release from tumor cell lines, cells were irradiated
with 20 Gy of gamma radiation for 30 min at room
temperature. As controls, cells were left at room temperature
for 30 min. 72 h later, supernatant was collected to assess
HMGB1 release by Western blot or HMGB1 specific ELISA.
To assess whether tumor cell lines release HMGB1 following
treatment with chemotherapy, cells were incubated with
temozolomide at a final concentration of 200 lM [41]. 48 h
later, supernatant was collected to assess HMGB1 release by
Western blot or HMGB1 specific ELISA.
Statistical Analysis
Due to difficulties in verifying normality of distribution
when the sample size is small, we used the following
nonparametric tests, i.e., Mann-Whitney U-test was used to
determine whether two independent samples (cohorts) came
from the same population, and the Kruskal-Wallis H test
followed by Dunn’s test was used to determine if several
independent samples came from the same population; these
tests were calculated using NCSS 2007 software (NCSS). Curve
inequality (phagocytosis and MLR experiments) was assessed
using the randomization test; also implemented on NCSS
2007 software (NCSS). All data are represented using scatter
plots. The effect size reported for the Mann-Whitney U-test
and the Kruskal-Wallis H test is partial g2 (eta-squared) and
was calculated using MINSIZE2 (kindly provided by David T.
Morse, Department of Counseling & Education Psychology,
Mississippi State University, Mississippi State, Mississippi,
USA [42–45]). Kaplan-Meier survival curves were analyzed
using the Mantel log-rank test and the effect size is expressed
as the median survival ratio (MSR); this was calculated using
GraphPad Prism version 3.00 (GraphPad Software). p-Values
of less than 0.05 were considered significant. The statistical
tests used are indicated within the figure legends. Sample
sizes were calculated to detect differences between groups
with a power of 80% at a 0.05 significance level using PASS
2008 (Power and sample size software, NCSS).
Results
Intratumoral Expression of Flt3L and TK Eliminates Brain
Tumors in a T Cell-Dependent Manner
To uncover the role of TLR signaling in brain tumor
regression and immunological memory, we developed a
syngeneic, intracranial mouse glioma model; treatment
consisted of intratumoral delivery of Ads expressing Flt3L
and TK (Ad-TKþAd-Flt3L), followed by systemic delivery of
GCV. We observed long-term survival after treatment (.150
d) in 50% of tumor-bearing WT mice treated with Ad-TK þ
Ad-Flt3L (*, p , 0.05 versus saline; MSR 4.1; Figure 1A) and
failure to improve survival in Rag1/, CD4/, or CD8a/mice
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(all on C57BL/6 background) compared with WT controls
(Figure 1B), indicating T cell-dependent tumor regression.
This treatment also elicited anti-GBM immunological mem-
ory (*, p , 0.05 versus saline; MSR 3.2; Figure 1C). To
investigate whether clonal expansion of tumor antigen
specific T lymphocytes occurred in response to Flt3L and
TK treatment, we pulsed BMDCs with GL26 brain tumor cell
extracts or LLc1 lung carcinoma cell extracts, and incubated
these BMDCs with T lymphocytes isolated from tumor-
bearing mice. The frequency of T cell precursors that
released IFNc in response to specific tumor antigens was
increased in mice implanted with GBM and treated with Flt3L
and TK (TF) (*, p , 0.05; Figure 1D). Analysis of the effect size
revealed a partial eta-squared (g2) value of 0.69, considered to
be a large effect [44–46]. Trp2180–188, a known H2-K
b-
restricted melanoma tumor antigen shared by glioma tumors
such as GL26 cells [47,48], also induced proliferation of T
lymphocytes from glioma-bearing mice treated with Flt3L
Figure 1. Flt3L and TK Recruits DC into Brain Tumors and Mediates T Cell–Dependent Brain Tumor Regression
(A) GL26 cells were implanted in the striatum of C57BL/6 mice. Tumor-bearing mice were treated 17 d later with Ad-Flt3L and Ad-TK (black solid line, n¼
6), Ad-TK (blue solid line, n¼ 6), Ad-Flt3L (purple solid line, n¼ 5), Ad0 (orange solid line, n¼ 4), or saline (black broken line, n¼ 6). Treatment with Ad-
Flt3L and Ad-TK significantly improved survival; *, p , 0.05 versus saline (Mantel log-rank test).
(B) GL26 cells were implanted in the striatum of WT (black, n¼6), or Rag1/ (Rag10, blue , n¼5), CD4/ (CD40, purple, n¼4), or CD8/ (CD80, orange, n
¼ 5) knockout mice. 17 d later, mice were treated with Ad-Flt3L and Ad-TK (solid lines) or saline (broken lines). Treatment with Ad-Flt3L and Ad-TK
significantly improved survival of WT animals when compared to all other strains; (*, p , 0.05; Mantel log-rank test).
(C) Long-term survivors (.150 d post-tumor cell implantation) were rechallenged with GL26 cells in the contralateral hemisphere (solid line, n ¼ 4).
Naı¨ve, age matched C57BL/6 mice were also implanted with GL26 cells as a control (broken line, n ¼ 5). Only long-term survivors showed increased
survival following tumor rechallenge (*, p , 0.05 versus saline; Mantel log-rank test).
(D) Tumor antigen specific, IFNc-producing T lymphocytes were quantified using an IFNc ELISPOT. GL26 cells were implanted in the brains of C57BL/6
mice and treated 17 d later with Ad-Flt3L and Ad-TK (TF) or Saline (S). T cells were isolated and incubated with DC loaded with either GL26 tumor
antigen (GL26) or LLc1 tumor antigen (LLc1) before quantification of IFNc production. Inset: Concanavalin A (ConA)-stimulated splenocytes (þ) are
shown as a positive control. *, p , 0.05 versus saline (Mann-Whitney U-test).
(E) A T cell proliferation assay was used to determine the percentage of T cells that recognize the tumor antigen Trp2180–188. GL26 cells were implanted
in the brains of mice, and treated after 17 d with Ad-Flt3L and Ad-TK or with saline. Splenocytes were isolated 7 d later and stained with CFSE, then
incubated with (þ) or without () Trp2180–188. CD8þ T cell proliferation was calculated using flow cytometry by quantifying the percentage of cells that
had divided (sequential dilution of CFSE fluorescence). *, p , 0.05 versus saline (Mann-Whitney U-test). Inset: Reverse transcriptase PCR confirms the
expression of Trp2 mRNA by GL26 cells. GAPDH primers were used as a control.
(F) GL26 cells were implanted in the brain of C57BL/6 mice and treated 17 d later with Ad-Flt3L and Ad-TK, Ad0, or saline. The total number of tumor-
infiltrating DCs (CD11cþ CD45High MHC IIþ) was quantified by flow cytometry. *, p , 0.05 versus saline (Kruskal-Wallis test followed by Dunn’s test).
Representative dot plots display tumor-infiltrating CD45þ immune cells stained with CD11c (x-axis) and MHC II (I-Ab; y-axis). DCs were identified as
(CD11cþ CD45High MHC IIþ). The total number of tumor-infiltrating mDC is indicated for each plot.
doi:10.1371/journal.pmed.1000010.g001
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and TK (*, p , 0.05 versus saline; g2 ¼ 0.43; Figure 1E)
confirming that clonal expansion of T lymphocytes against a
specific glioma antigen occurs in response to treatment.
In order to mount a specific antitumor immune response,
DCs need to infiltrate the tumor mass where they can
phagocytose tumor antigen, and migrate to the cervical dLN
to elicit clonal expansion of antitumor specific T cells. The
number of mDCs (CD11cþ; CD45þ; MHC IIþ) isolated from the
tumors increased almost 10-fold in WT C57BL/6 mice 7 d
after treatment with Flt3L and TK compared with saline
treated controls (*, p , 0.05 versus saline; g2 ¼ 0.54; Figure
1F).
Tumor-Infiltrating DCs, in Response to Flt3L and TK
Treatment, Originate from the Bone Marrow
To investigate whether CD11cþ tumor-infiltrating immune
cells originate from bone marrow, we generated bone marrow
chimeric mice. To do so, we adoptively transferred GFPþbone
marrow into irradiated WT mice, or conversely transplanted
WT bone marrow into irradiated GFPþ mice. 10 wk after
adoptive transfer, mice were implanted with GL26 tumor cells
in the striatum. We treated tumor-bearing chimeric mice with
Ad-Flt3L and Ad-TK 17 d post-tumor implantation and
characterized the origin of tumor-infiltrating CD11cþ mDC
Figure 2. Tumor-Infiltrating DC Are Bone Marrow Derived
(A–F) Bone marrow chimeric mice were used to assess the origin of CD11cþ mDC infiltrating into the tumor. (A,C,E) WT mice are depicted on the left
panels; chimeras are as follows: WT mice adoptively transferred with GFPþ/þ bone marrow; or GFPþ/þmice adoptively transferred with WT bone marrow;
GFPþ/þ mice are depicted on the right panels. GL26 cells were implanted in all mice 10 wk after irradiation and treated 17 d later with Ad-Flt3L and Ad-
TK. 7 d after the treatment, tumor-infiltrating immune cells and splenocytes were isolated; flow cytometry was performed to detect total GFPþ
splenocytes (A and B), GFPþ tumor-infiltrating microglia (C and D), or GFPþ tumor infiltrating mDC (E and F).
Representative dot plots show (A) GFPþ (upper boxes, GFPþ, CD45hi) or GFP splenocytes (lower boxes, GFP, CD45hi); (C) GFPþ microglia (upper boxes,
GFPþ, CD45Int) or GFP microglia (lower boxes, GFP, CD45Int); and (E) GFPþ mDC (upper boxes, GFPþ, CD11cþ) or GFP mDC (lower boxes, GFP,
CD11cþ) infiltrating into the brain tumors.
The normalized percentage of GFPþ splenocytes (B), tumor-infiltrating GFPþ microglia (D), and tumor-infiltrating GFPþ mDC (F) are shown for each type
of chimeric mouse (*, p , 0.05; Mann-Whitney U-test).
doi:10.1371/journal.pmed.1000010.g002
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7 d after treatment. To visualize total splenocytes or tumor-
infiltrating microglia, live immune cells were gated (FSC
versus SSC), and CD45 was plotted against GFP fluorescence
(Figure 2A and 2C). To visualize tumor-infiltrating mDC, live
CD45þ immune cells were gated and CD11c was plotted
against GFP (Figure 2E). The majority of splenocytes in the
chimeric mice exhibited the phenotype of the donor mice (*, p
, 0.05; g2 ¼ 0.75; Figure 2A and 2B). Microglial cells, or any
brain resident immune cells are radio-resistant because of
their low mitotic rate [49], and thus most microglia exhibited
the phenotype of recipient mice (*, p , 0.05; g2¼0.75; Figure
2C and 2D). If CD11cþ immune cells that infiltrate into the
brain tumor originate from the bone marrow, they would
exhibit the phenotype of the adoptively transferred bone
marrow; if they were to originate from CNS sources they
would retain the phenotype of the recipient mice. In chimeric
mice generated by adoptively transferring bone marrow from
GFPþ/þ mice into irradiated WT mice, 22.23% (65.64%) of
tumor-infiltrating mDC were GFPþ. In chimeric mice gen-
erated by adoptively transferring bone marrow fromWTmice
into irradiated GFPþ/þ mice; 2.24% (60.32%) of tumor-
infiltrating mDC were GFPþ (Figure 2E). Since 0% of mDC
from WT mice displayed the phenotype of GFPþ CD11cþ
mDC, and 29.27% of cells from GFPþ/þ mice displayed the
phenotype of GFPþ CD11cþ mDC (Figure 2E), we calculated
the normalized percentage of GFPþmDC infiltrating into the
tumors of each chimeric mouse from the data shown in Figure
2E using the following equation: %normalized GFPþ mDC ¼
[%GFPþ mDC in the chimera  0% (background)]/
[29.27%(GFPþ mDC in GFPþ/þ mice)  0% (background)] 3
100. We found that 75.95% (619.25%) of tumor-infiltrating
mDC in chimeric mice generated by adoptively transferring
bone marrow from GFPþ/þ mice into irradiated WT mice
(white) could be conclusively identified as originating from
bone marrow. This was significantly greater (*, p , 0.05; g2¼
0.75) than the 7.65% 6 1.08% GFPþmDC encountered in the
chimeric mice generated by adoptively transferring bone
marrow from WT mice into irradiated GFPþ/þ mice (black)
(Figure 2F). Therefore, our data suggest that the vast majority
of CD11cþ-infiltrating immune cells in Ad-Flt3L and Ad-TK-
treated brain tumors are bone marrow-derived mDC.
TLR2 Expression on BMDC Is Necessary for Tumor
Regression
To determine if TLRs were involved in mediating the
efficacy of the combined antiglioma treatment, we inves-
tigated whether Myd88 knockout mice would respond to our
therapy, as Myd88 is required for downstream signaling from
every TLR except TLR3 [12,50]. Treatment with Flt3L and TK
failed to eliminate brain tumors in Myd88/mice (Figure 3A)
suggesting that one or more TLR signaling pathways are
required for T cell-dependent tumor regression in this
Figure 3. TLR2 Signaling Mediates T Cell-Dependent Brain Tumor
Regression
(A) TLR2 and Myd88 are required for Ad-Flt3L and Ad-TK mediated brain
tumor regression. GL26 cells were implanted into C57BL/6, Myd88/,
TLR4/, and TLR2/mice. 17 d later C57BL/6 (solid black, n¼7), Myd88/
 (solid purple, n¼ 5), TLR4/ (solid blue, n¼ 5), and TLR2/ mice (solid
red, n ¼ 9) were treated with an intratumoral injection of Ad-Flt3L and
Ad-TK (solid lines). As controls, C57BL/6 (dashed black, n ¼ 7), TLR4/
(dashed blue, n¼ 4), and TLR2/ mice (dashed red, n¼ 6) were treated
with saline. *, p , 0.05 versus saline; Mantel log-rank test.
(B) GL26 cells were implanted in the striatum of TLR2/mice and treated
17 d later with Ad-Flt3L and Ad-TK, Ad0, or saline. Flow cytometry was
used to quantify the total number of tumor-infiltrating DCs (CD11cþ
CD45High MHC IIþ). Kruskal-Wallis test. Inset: Representative dot plots
display tumor-infiltrating CD45þ immune cells stained for CD11c (x-axis)
and MHC II (I-Ab; y-axis). DCs were identified as (CD11cþCD45High MHC IIþ).
The total number of tumor-infiltrating mDC are indicated for each plot.
(C) Treatment of tumor-bearing TLR2/ mice with Ad-Flt3L and Ad-TK
fails to induce clonal expansion of tumor antigen specific T lymphocytes.
GL26 cells were implanted in the brains of TLR2/mice and treated with
Ad-Flt3L and Ad-TK (FT) or saline (S) after 17 d. T cells were purified from
the spleens 7 d later and incubated with WT DC loaded with GL26 tumor
extracts (GL26) or with syngeneic LLc1 carcinoma cell extracts (LLc1)
before quantification of IFNc producing cells by ELISPOT. Mann-Whitney
U-test. Inset: Concanavalin A (ConA) stimulated splenocytes (þ) are also
shown as a positive control.
doi:10.1371/journal.pmed.1000010.g003
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model. Importantly, TLR2 and TLR4 have recently been
demonstrated to play a role in models of brain inflammation
[51–53], and several endogenous TLR2 and TLR4 ligands such
as gp96, HMGB1, HSP60, HSP70, and hyaluronan have been
identified in various tumors [54–58]. Thus, we tested the role
of TLR2 and TLR4 in TK- and Flt3L-mediated glioma
regression. Analysis of brain sections by immunohistochem-
istry with antibodies specific for Flt3L and TK confirmed that
both therapeutic transgenes were efficiently expressed in the
brains of TLR2/ and TLR4/ mice (unpublished data).
Treatment with Flt3L and TK failed in TLR2/mice, whereas
it significantly improved survival of TLR4/mice (*, p , 0.05
versus saline; MSR 1.55; Figure 3A). These data demonstrate
that TLR2, but not TLR4, mediates T cell-dependent brain
tumor regression in this model. Unlike WT mice (Figure 1F)
tumor-infiltrating mDCs did not increase in Flt3L- and TK-
treated TLR2/ mice (Figure 3B); indicating that the
migration of DCs into the tumor mass in response to TK
and Flt3L treatment is TLR2 dependent. Further, the
frequency of tumor antigen specific T lymphocytes did not
increase in treated TLR2/mice (Figure 3C). Treatment with
Flt3L and TK induced proliferation of CD4þ (*, p , 0.05
versus saline; g2 ¼ 0.76; Figure S4A) and CD8aþ T
lymphocytes (*, p , 0.05 versus saline; g2 ¼ 0.74; Figure
S4B) in the draining LN of tumor-bearing WT mice, but not
their TLR2/ counterparts.
TLR2 signaling in DCs mediates upregulation of costimu-
latory molecules and facilitates clonal expansion of antigen
specific T lymphocytes [59,60]. Thus, we wished to investigate
whether TLR2 signaling on tumor-infiltrating DCsmediated T
cell-dependent tumor regression in our model. To do this, the
following experiments were performed in bone marrow
chimeric mice: (1) irradiated TLR2/ mice were adoptively
transferred with WT bone marrow, and (2) WT mice were
irradiated and were adoptively transferred with TLR2/ bone
marrow (Figure 4A); both sets of chimeric animals were
implanted with tumors and treated with Ad-Flt3L and Ad-TK.
Tumor regression was only observed in irradiated TLR2/
mice adoptively transferred withWTbonemarrow (*, p, 0.05;
MSR 1.8; Figure 4B); this strongly suggests that TLR2
expression is necessary on bone marrow-derived, tumor-
infiltrating immune cells. Next, we wished to determine
whether TLR2 signaling exclusively on BMDCs was sufficient
to induce brain tumor regression. To this end, we implanted
BMDC (Figure 5A) loaded with GL26 extracts into the tumor
mass. Intratumoral delivery of WT DC pulsed with GL26
Figure 4. TLR2 Signaling on Bone Marrow-Derived Immune Cells and Not Microglia Is Necessary for Brain Tumor Regression
(A) Schematic describing the generation of chimeric mice and subsequent implantation of tumors and treatment. WT irradiated C57BL/6 mice were
adoptively transferred with TLR2/ bone marrow (top); TLR2/ irradiated mice were adoptively transferred with WT bone marrow (bottom). 70 d later
chimeric animals were implanted with tumor cells and treated with Ad-Flt3L and Ad-TK, 17 d post-tumor implantation.
(B) Kaplan-Meier curve depicting survival when chimeric mice were challenged with intracranial GBM and treated with Ad-Flt3L and Ad-TK (wt type
bone marrow, black line, n¼ 5; TLR2/ bone marrow, red line, n¼ 4). (*, p , 0.05, Mantel log-rank test).
doi:10.1371/journal.pmed.1000010.g004
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tumor extract mediated regression of intracranial brain
tumors in WT mice (*, p , 0.05 versus saline; MSR 1.2; Figure
5B), whereas TLR2/-derived DC pulsed with GL26 tumor
extract failed to induce brain tumor regression (Figure 5B).
Together, our results demonstrate that endogenous activation
of TLR2 on tumor-infiltrating BMDCs is necessary for
initiating T lymphocyte clonal expansion and tumor regres-
sion.
TLR2 Is Necessary for DC Activation and Antigen
Presentation
Previous studies have shown that necrotic cell extracts can
stimulate DC activation [61]. We hypothesized that tumor cell
necrosis could release endogenous TLR2 ligands and thus
activate DC. Our results show that necrotic GL26 and other
tumor cells induced TLR2 dependent; TLR4 independent,
activation of NFjB-signaling (Figure S5), suggesting that
endogenous TLR2 ligand(s) released upon cell death could
activate the TLR2-dependent NFjB signal transduction
pathway. Activation of TLR signaling pathways on DC can
differentially modulate phagocytosis of tumor cell fragments,
costimulatory molecule expression, and production of in-
flammatory cytokines [62]. We investigated whether endoge-
nous TLR2 activity on BMDC was important for phagocytosis
of tumor cell remnants, proliferation of tumor antigen
specific T lymphocytes, and expression of inflammatory
cytokines. Both WT and TLR2/BMDC phagocytosed labeled
GBM cell lysates (Figure 6A and 6B). DC activation in
response to GL26 tumor extracts was dependent on TLR2
expression; we observed that the release of the pro-
inflammatory cytokines TNFa and IL6 was elevated when
WT BMDC were incubated with either media from GL26 cells
killed with Ad-TK and GCV or necrotic GL26 cells (*, p, 0.05
versus mock; Figure 6C, g2¼ 1.0; Figure 6D, g2¼ 0.73). TNFa
release was not increased from TLR2/ DC incubated with
either media from GL26 cells killed with Ad-TK (þGCV) or
necrotic GL26 cells (Figure 6C). IL6 release did not increase
in TLR2/DC incubated with media from GL26 cells treated
with Ad-TK (þGCV) (Figure 6D). We next investigated
whether TLR2 signaling was required to induce T cell
proliferation in both allogeneic and syngeneic, antigen-
specific mixed lymphocyte reaction assays (MLR). WT BMDC
(*, p , 0.05; Figure 6E) but not TLR2/ BMDC (Figure 6E)
promoted allogeneic T lymphocyte proliferation. Next we
determined that only WT BMDC, but not TLR2/ BMDC
pulsed with GL26 cell extracts induced proliferation of tumor
antigen specific T lymphocytes (*, p , 0.05, Figure 6F). Thus,
TLR2 signaling on DC in response to GL26 tumor cells is
necessary for DC activation and presentation of tumor
antigen to T lymphocytes.
HMGB1 Is the Endogenous Ligand That Mediates TLR2-
Dependent Glioma Tumor Regression.
We hypothesized that endogenous TLR2 ligands would also
be released from GL26 cells treated with Ad-TK þ GCV. In
turn, endogenous TLR2 ligands could play a role in tumor
regression. Interestingly, it was recently shown that HMGB1
released from lymphoma, breast, and colon tumor cells
enhances tumor regression induced by standard chemo-
therapeutic agents by activating TLR4 [9]. HMGB1 can also
activate TLR2 in addition to TLR4 and differential TLR
activation appears to depend on the particular tumor model
used [58]. Therefore, we hypothesized that HMGB1 could be
an endogenous TLR2 ligand released from TKþGCV treated
GL26 cells. Our results show an increase in extracellular
HMGB1 (approximately 30 kDa MW detected by western blot)
released from Ad-TKþGCV treated GL26 tumor cells in vitro
48 h and 72 h after treatment (Figure 7A). This event
occurred concomitantly with the binding of Annexin V to
phosphatidylserine and the formation of a typical DNA
ladder, which is the hallmark of apoptotic cells (Figure S6). To
investigate whether HMGB1, released from dying GL26
tumor cells (Ad-TK þ GCV treated), was responsible for
TLR2 activation in vitro, we inhibited HMGB1 binding using
glycyrrhizin, a known antagonist of HMGB1 [40,63]. Glycyr-
Figure 5. TLR2 Signaling on BMDCs Is Necessary for Brain Tumor
Regression
(A) CD11cþ mDC were generated from bone marrow of C57BL/6 mice
(left) or TLR2/ mice (right) and identified using flow cytometry.
(B) GL26 cells were implanted in the brains of WT mice, and 7 d later mice
were treated with an intratumoral injection of WT BMDCs loaded with
GL26 tumor extracts (black, n ¼ 5), TLR2/ BMDCs loaded with GL26
tumor extracts (red, n ¼ 4), or saline (dashed black, n ¼ 5). *, p , 0.05
versus saline; Mantel log-rank test.
doi:10.1371/journal.pmed.1000010.g005
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Figure 6. TLR2 Is Necessary for DC Activation and Antigen Presentation but Not for Tumor Phagocytosis In Vitro
Extracts were made of GL26 cells labeled with PKH-67 and incubated with WT (A) or TLR2/ (B) BMDC for 16 h either at 4 8C or 37 8C. The percentage of
CD11cþ DC that phagocytosed labeled GL26 cell extracts (green boxes) was quantified by flow cytometry. The scatter plots depict the rate of
phagocytosis of PKH67 labeled GL26 cells by WT (A) and TLR2/ (B) DC every 2 h for 6 h at 4 8C and 37 8C. *, p , 0.05 versus 4 8C (randomization test).
PLoS Medicine | www.plosmedicine.org January 2009 | Volume 6 | Issue 1 | e10000100095
Endogenous HMGB1 Induces TLR2 Signaling
rhizin completely blocked TLR2-dependent NFjB activation
by supernatants from dying (Ad-TK þ GCV treated) GL26
cells (*p , 0.05; g2¼ 0.75; Figure 7B) indicating that HMGB1
secreted from GL26 cells stimulates TLR2 signaling. We next
investigated whether HMGB1 was released into the serum of
GBM-bearing mice treated with Ad-TK þ GCV and Flt3L in
vivo. HMGB1 was increased in the serum of tumor-bearing
mice 7 d after treatment with Flt3L and TK (*p , 0.05; g2 ¼
0.49; Figure 7C), suggesting that HMGB1 released from dying
tumor cells might be responsible for activating TLR2 on DC
in vivo and subsequent T cell-dependent tumor regression.
To test the hypothesis that HMGB1 secreted from GBM-
bearing mice after treatment with Flt3L plus TK (GCV)
mediates TLR2 signaling and T cell-dependent brain tumor
regression in vivo, we blocked circulating HMGB1 in vivo
using glycyrrhizin or specific anti-HMGB1 immunoglobulins.
HMGB1 antibodies were generated by us, using the N-
terminal 11 amino acids of the HMGB1 peptide sequence
previously described (Figure S3A) [39]. The anti-HMGB1
antibodies, recognized a single ;30-kDa band from GL26 cell
lysates by western blot (Figure S3B). Inhibition of extrac-
ellular HMGB1 activity in vivo using either blocking anti-
bodies or glycyrrhizin resulted in the complete failure of our
therapy (Figure 7D). Together, our data provide compelling
evidence that HMGB1, released from GBM tumors treated
with Ad-Flt3L and Ad-TK in vivo, elicits TLR2 signaling that
results in recruitment of BMDC into the tumor mass, with
concomitant induction of antitumor specific T cell clonal
expansion, long-term survival, and immunological memory.
HMGB1 Is Released from Several Tumor Cell Lines When
Treated with Either Ad-TK (þGCV), Radiation, or
Chemotherapy
To assess whether HMGB1 release is specific to Ad-TK
(þGCV)-induced GL26 cell-killing or a more general phe-
nomenon, we treated GL26 (glioma), LLc1 (lung carcinoma),
GL261 (glioma), or B16-F10 (melanoma) cells in vitro with
three different cell-killing modalities currently in use in the
clinic or clinical trials for brain tumors: either Ad-TK
(þGCV), radiation, or chemotherapy (temozolomide). West-
ern blot analysis of cell culture supernatants revealed
increased levels of HMGB1 following treatment with either
Ad-TK (þGCV), radiation, or temozolomide (Figure 8). We
then performed a HMGB1-specific ELISA to quantitate the
levels of HMGB1 release from GL26, LLc1, GL261, or B16-F10
cells in vitro following treatment with either Ad-TK (þGCV),
radiation, or temozolomide. Figure 9A–9D reveals statistically
significant increases (*p , 0.05 versus mock and Ad0) in
HMGB1 levels in the supernatants of GL26 (g2 ¼ 0.67), LLc1
(g2¼ 0.68), GL261 (g2¼ 0.73), or B16-F10 cells (g2¼ 0.72) in
response to Ad-TK (þGCV). Irradiation (Figure 9E–9H) and
temozolomide (Figure 9I–9L) treatments also caused a
significant increase (*, p , 0.05) in the levels of HMGB1
released from GL26 (g2 ¼ 0.60 and 0.63, respectively), LLc1
(g2 ¼ 0.60 for both treatments), GL261 (g2 ¼ 0.60 for both
treatments), and B16-F10 tumor cells (g2 ¼ 0.67 and 0.60,
respectively). Taken together, these data strongly suggest that
HMGB1 release following treatment of tumor cells with a
variety of cytotoxic agents is a wide-spread phenomenon
regardless of tumor cell type or tumor cell killing approach.
Treatment of Mice Bearing a Second Variant of Intracranial
Glioma (GL261) or Melanoma (B16-F10) Tumors with Ad-
Flt3L and Ad-TK (þGCV) Results in Long-Term Survival and
Increased Serum Levels of HMGB1
We next investigated the therapeutic efficacy of Ad-Flt3L
and Ad-TK (þGCV) in vivo in mice bearing intracranial
tumors derived from GL261 or B16-F10 cells and whether
HMGB1 was released into their serum following treatment.
We observed that intratumoral delivery of Ad-Flt3L and Ad-
TK (þGCV) elicited long-term survival (.60 d) in 60% of WT
mice bearing GL261 (*, p , 0.05 versus saline; Figure 10A)
and in 40% of mice bearing B16-F10 tumors (*, p , 0.05
versus saline; MSR 1.57; Figure 10C). Ad-Flt3L or Ad-TK
failed to elicit long-term survival when administered individ-
ually. Levels of HMGB1 were increased in the serum of mice
bearing either GL261 (*, p , 0.05; g2 ¼ 0.67; Figure 10B) or
B16-F10 tumors (*, p , 0.05; g2¼ 0.54; Figure 10D) 7 d after
treatment with Flt3L and TK. These data demonstrating
therapeutic efficacy of intratumoral administration of Ad-
Flt3L and Ad-TK in tumors derived from two other cell lines
suggest that this combined immunotherapy could be effective
against a wide range of primary and metastatic brain tumors.
Also, increased levels of HMGB1 in the serum of mice bearing
GL261 or B16-F10 tumors after treatment with Ad-Flt3L and
Ad-TK indicate that HMGB1 release is not limited to tumor
derived from GL26 cells, and in fact, is released from tumors
originating from various other cell types.
Discussion
This paper elucidates the mechanisms that mediate an
antibrain tumor immune response directly from within the
tumor microenvironment. Utilizing syngeneic brain tumor
models we demonstrate that it is possible to stimulate a
systemic antitumor immune response by modifying the brain
tumor microenvironment through the recruitment of DCs to
the tumor milieu in combination with tumor cell killing.
Further, we demonstrate an essential link that has so far been
difficult to determine. Namely, it has been known for some
time that stimulation of the innate immune system is
necessary to achieve activation of the systemic adaptive
Secretion of TNFa (C) and IL6 (D) from WT DC (black) or TLR2/ DC (red) was determined by ELISA after incubation with: GL26 cell extracts, media from
GL26 cells infected with Ad-TK (with and without GCV), or media (unstimulated controls). Inset: Pam3CSK4-treated DCs (positive control). *, p , 0.05
versus unstimulated controls (Kruskal-Wallis test followed by Dunn’s test).
(E) An allogeneic mixed leukocyte reaction (MLR) was used to determine whether DC could stimulate T cell proliferation. DC (stimulators) from C57BL/6
mice (left panel, black) or TLR2/ mice (right panel, red) were incubated with GL26 cell extracts before adding to allogeneic naı¨ve Balb(c) T cells
(responders). BrdU incorporation into DNA was measured to determine relative proliferation of T cells. BMDC that were not loaded with GL26 cell
extracts were used as a control for background T cell proliferation (dashed lines). *, p , 0.05 versus unloaded DCs; randomization test.
(F) A syngeneic MLR was used to determine if TLR2 activation on DCs can induce tumor antigen specific T cell proliferation. DC (stimulators) from WT
mice (left panel, black) or TLR2/ mice (right panel, red) were incubated with GL26 cell extracts and added to tumor antigen specific T cells
(responders). BrdU incorporation into DNA was measured to determine relative proliferation of T cells. BMDC that were not loaded with GL26 cell
extracts were used as a control for background T cell proliferation (dashed lines). *, p , 0.05 versus unloaded DCs; randomization test.
doi:10.1371/journal.pmed.1000010.g006
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immune response. However, how this is achieved in tumors,
in the absence of exogenous activators of TLR signaling has
remained elusive. Clinically, tumor immunization paradigms
have attempted to provide innate immune stimulation
through the administration of vaccines with known TLR
activators, such as CpG [64,65].
Herein, we demonstrate that treatment of brain tumors
with Ad-TK (þGCV) and Ad-Flt3L injected directly into the
brain tumor microenvironment stimulates a systemic adap-
tive antiglioma immune response. Furthermore, we show that
this treatment is strictly dependent on the activation of TLR
signaling on bone-marrow DCs that infiltrate the tumor. We
Figure 7. HMGB1 Is Secreted from Dying Tumor Cells and Is Required for Ad-Flt3L and Ad-TK Mediated Brain Tumor Regression
(A) GL26 cells were infected with Ad-TK and incubated with 25 lM GCV. A western blot was performed using an antibody specific for HMGB1. The graph
displays a quantification of the total amount of HMGB1 in the media of cells 24 h (yellow bars), 48 h (orange bars), or 72 h (black bars) after GCV treatment.
(B) GL26 cells were incubated with Ad-TK (with and without GCV and glycyrrhizin), and media was overlaid on HEK293 reporter cells transfected with
either a plasmid encoding TLR2 (þpTLR2; black) or with a control plasmid (-pTLR2; red). NFjB activity was determined by quantifying the activity of
Firefly Luciferase (under the control of the NFjB promoter), *, p , 0.05 (Kruskal-Wallis followed by Dunn’s test). Inset: cells were incubated with 100 ng/
ml PAM3 (PAM3CSK4) as a positive control.
(C) The levels of HMGB1 in mouse serum were quantified by ELISA 7 d after treatment of brain tumors with Ad-Flt3L and Ad-TK. *, p, 0.05 versus saline
(Mann-Whitney U-test).
(D) GL26 cells were implanted into C57BL/6 mice (n¼ 5 mice/treatment group) and 17 d later were treated with saline, or with AdFlt3L and Ad-TK (F/T).
Glycyrrhizin (Glyc), HMGB1-depleting (aHMGB1), or rabbit IgG isotype control antibodies were administered IP 2 d, 5 d, and 10 d after treatment, *, p ,
0.05 Ad-Flt3L and Ad-TK versus Ad-Flt3L and Ad-TK þ glycyrrhizin; ^p , 0.05 Ad-Flt3L and Ad-TK þ isotype versus Ad-Flt3L and Ad-TK þ aHMGB1;
Mantel log-rank test.
doi:10.1371/journal.pmed.1000010.g007
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went further to identify glioma-derived HMGB1 as the
endogenous TLR2 ligand, whose signaling is necessary to
elicit systemic adaptive immune-mediated GBM regression
and long-term immunological memory in an intracranial
glioma model (Figure 11) [51,66].
Injured tissue can trigger inflammatory and auto-immune
responses owing to the release of endogenous molecules that
activate signaling cascades that mediate DC activation and T
cell clonal expansion [67]. Several injury-associated molecules
have been recently identified that mediate their effects by
signaling through TLRs. For example, TLR2 signaling can be
stimulated in response to host-derived molecules including
gp96 [57,68], HMGB1 [69], low molecular weight hyaluronan
fragments [55], soluble CD14 [29,70], and possibly larger
hydrophobic molecular complexes (Hyppo’s) [71].
Many of these endogenous ligands, such as HMGB1 [72],
CD14 [70], and HSP70 [73], are expressed by brain tumor
cells. Here we show that dying glioma cells released HMGB1,
as a result of infection and killing with Ad-TK (þGCV);
HMGB1 in turn stimulated TLR2-dependent NFjB signaling
and DC activation. Importantly, we never observed any
evidence for brain autoimmunity in these studies, or in our
prior work [8,74–76], nor is it observed clinically in patients
surviving a stroke, or following brain surgery [2]. Further, T
cell-dependent tumor regression failed in vivo in TLR2
knockout mice, or mice where HMGB1 is either depleted or
functionally inactivated. This strongly suggests that HMGB1
is the main, if not unique, endogenous activator of TLR2
signaling and necessary innate immune activation.
We used two different inhibitors of HMGB1 to block the
activity of the putative endogenous TLR2 ligand during the
combined immunotherapy-induced tumor regression. Glycyr-
rhizin binds to both box domains within HMGB1 [40,63] and
thus prevents subsequentHMGB1 signaling; specific polyclonal
blocking antibodies to HMGB1 [39,77–80] inactivate HMGB1
by binding to it, and reducing its bioavailability. Both pathways
of HMGB1 antagonism completely abrogated the therapeutic
efficacy of Ad-Flt3L plus Ad-TK. Glycyrrhizin binding to
HMGB1 effectively inhibits its chemoattractant properties
[63]. Glycyrrhizin has also been used to inhibit HMGB1-
mediated liver disease in a model of viral hepatitis [40]. Other
investigators have used different polycolonal antibodies raised
against small peptides within Box A [39,77] or Box B [78–80] of
HMGB1 to successfully inhibit HMGB1 activity in animal
models of collagen-induced arthritis, sepsis, liver ischemia
reperfusion injury, and intestinal barrier dysfunction follow-
ing hemorrhagic shock. Whether additional proteins released
from the tumor are able to stimulate other TLR pathways has
not been determined. Importantly for our experimental
paradigm, however, blocking HMGB1 alone was sufficient to
completely abrogate the efficacy of the antiglioma treatment.
Our results demonstrate that glioma-derived HMGB1
released from dying cells is necessary for the clonal expansion
of CD8þ T cells specific for glioma antigens including the
Trp2180–188 peptide (H-2K
b), and that the effects of HMGB1
are mediated through TLR2 signaling on tumor-infiltrating
DCs. Importantly, HMGB1 released from dying GBM cells
after treatment with TK (þGCV), on its own, was insufficient
to induce tumor regression in our model. This result is shown
by the failure of Ad-TK (þGCV) alone to eliminate brain
tumors. Only the combined treatment of tumors with Ad-
Flt3L and Ad-TK (þGCV) overcame immune ignorance to
tumor antigens located within the brain. This indicates that
expression of Flt3L is necessary to induce the migration and
Figure 8. Western Blot Analysis Reveals HMGB1 Is Released from GL26, LLc1, GL261, and B16-F10 Cell Lines Following Treatment with Ad-TK (þGCV),
Irradiation, or Temozolomide (TMZ)
(A) LLc1, GL261, or B16-F10 cells were infected with Ad-TK or Ad-0 at an MOI¼500. Noninfected cells were used as control. Ad-TK treated cells were also
incubated with 25 lM GCV. 48 h later, supernatant was collected and HMGB1 release was assessed by western blotting.
(B) GL26, LLc1, GL261, or B16-F10 cells were irradiated with 20 Gy for 30 min. Nonirradiated cells were used as control. 72 h later, supernatant was
collected and HMGB1 release was assessed by western blotting.
(C) GL26, LLc1, GL261, or B16-F10 cells were incubated with temozolomide (TMZ) (200 lM). Control cells were incubated without TMZ (mock). 48 h later,
supernatant was collected and HMGB1 release was assessed by western blotting.
doi:10.1371/journal.pmed.1000010.g008
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differentiation of DCs within the tumor. By expressing Flt3L
directly within the brain tumor we achieved infiltration of
immune cells directly into the brain tumor microenviron-
ment, and stimulation of a systemic antitumor immune
response. We have previously shown that Flt3L recruits DCs
into the naı¨ve rat brain [7]. However, recruitment of immune
cells on its own also fails to eliminate the brain tumors [74].
Thus, both Flt3L-induced recruitment of immune cells to the
brain and TK-dependent release of the TLR2 agonist HMGB1
are necessary for tumor elimination; together, they are
sufficient to induce the regression of a large intracranial
glioma and melanoma tumors.
It is likely that HMGB1 released into the serum as a result
of tumor cell death mediates TLR2 signaling on BMDCs,
facilitating their subsequent activation within the tumor [81].
Our data indicate that DC do not infiltrate into the tumor
mass of TLR2/ mice after treatment with Flt3L and TK
(þGCV). The absence of TLR2 signaling on brain-infiltrating
immune cells abrogates tumor elimination. Thus, Flt3L is
necessary to recruit the appropriate immune cell types to the
Figure 9. HMGB1 Is Released into the Supernatant of GL26, LLc1, GL261, and B16-F10 Tumor Cell Lines in Response to Treatment with Ad-TK (þGCV),
Irradiation, or Temozolomide
(A–D) GL26, LLc1, GL261, or B16-F10 cells were infected with Ad-TK or Ad-0. Noninfected cells were used as control (mock). Ad-TK treated cells were
incubated with 25 lM GCV. 48 h later, supernatant was collected, and HMGB1 release was assessed by ELISA. Treatment with Ad-TK (þGCV) significantly
increased HMGB1 release when compared to corresponding mock and Ad0 treatment groups from each cell line, *, p , 0.05 versus mock and Ad-0
(Kruskal-Wallis test followed by Dunn’s test).
(E–H) GL26, LLc1, GL261, or B16-F10 cells were irradiated with 20 Gy for 30 min. Nonirradiated cells were used as controls (mock). 72 h later, supernatant
was collected, and HMGB1 release was assessed by ELISA. Treatment with irradiation significantly increased HMGB1 release when compared to
corresponding control groups from each cell line, *, p , 0.05 versus mock (Mann-Whitney U-test).
(I–L) GL26, LLc1, GL261, or B16-F10 cells (2.53105 cells per flask) were incubated with or without temozolomide (TMZ) (200 lM). 48 h later, supernatant
was collected, and HMGB1 release was assessed by ELISA. Treatment with TMZ significantly increased HMGB1 release when compared to control groups
from each cell type. *, p , 0.05 versus mock (Mann-Whitney U-test).
doi:10.1371/journal.pmed.1000010.g009
PLoS Medicine | www.plosmedicine.org January 2009 | Volume 6 | Issue 1 | e10000100099
Endogenous HMGB1 Induces TLR2 Signaling
brain tumor microenvironment, but TLR2 signaling must
then be activated on these cells by HMGB1 released from
dying tumor cells. Our data demonstrate that HMGB1-
mediated TLR2 signaling links the effects of Flt3L on the
recruitment of immune cells to the brain tumor micro-
environment to their capacity to induce a systemic antitumor
immune response.
Our data show that TLR2 signaling in response to
endogenous HMGB1 ligand released from dying tumor cells
needs to take place on BMDCs. Although our experiments
suggest that HMGB1 signaling occurs mainly through TLR2
activation, we cannot discard that other endogenous ligands
may be released that may act on TLR4, although our data in
TLR4/mice do not lend strong support for the role of TLR4
signaling in our model.
Our results also demonstrate long-term survival and
increased levels of circulating HMGB1 in the serum of Ad-
Flt3L þ Ad-TK (þGCV) treated animals bearing intracranial
melanomas. These data broaden the potential therapeutic use
of Ad-Flt3LþAd-TK for the treatment of other solid tumors,
and suggest that the same molecular mechanism described
initially could also be responsible for the elimination of
metastatic brain tumors. While the detailed experiments to
elucidate the role of HMGB1 and TLR2 signaling have only
been performed using the GL26 cells in C57Bl/6 mice, we
believe that the general effectiveness of the Ad-Flt3L and Ad-
TK therapeutic approach is likely to be mediated by the same
general underlying mechanism in both primary and meta-
static brain tumors [8,75,76]. The endogenous activation of
TLR signaling explains how activation of the innate immune
response can be achieved through tumor-derived ligands
during the induction of therapeutically effective and selective
antibrain tumor immune responses.
In conclusion, the results reported provide compelling
evidence for the role played by HMGB1 in mediating the
efficacy of antiglioma therapeutic regimes that are based on
tumor cell killing strategies, such as the HSV1-TK (þGCV)
conditional cytotoxic approach described herein and cur-
rently in Phase III clinical trials [82], or other currently
employed chemotherapeutic (e.g., temozolomide), and radio-
therapy regimes. A recent case study suggesting a potential
synergistic effect between temozolomide and an immuno-
therapy involving a tumor vaccination strategy [83] further
supports our hypothesis that cancer immunotherapies
Figure 10. Treatment of Animals Bearing Intracranial Glioma (GL261) or Melanoma (B16-F10) with Ad-Flt3L and Ad-TK (þGCV) Results in Long-Term
Survival and Increased Serum Levels of HMGB1
(A) GL261 cells were implanted into the striatum of C57/Bl6 mice. 17 d later animals were treated with Ad-Flt3L (n¼ 5), Ad-TK (þGCV) (n¼ 6), Ad-Flt3L
plus Ad-TK (þGCV) (n¼ 5), or saline (n¼ 5). Treatment with Ad-Flt3L and Ad-TK significantly improved survival when compared to saline (*, p , 0.05;
Mantel log-rank test), Ad-Flt3L, or Ad-TK alone treatment groups (^, p , 0.05; Mantel log-rank test). Treatment with Ad-Flt3L, or Ad-TK alone
significantly improved survival when compared to saline (*, p , 0.05; Mantel log-rank test).
(B) 7 d after treatment, tumor-bearing animals were humanely killed and HMGB1 release was assessed in the serum. Treatment of GL261 tumor-bearing
animals with Ad-Flt3L and Ad-TK (þGCV) significantly increased the levels of HMGB1 in the serum when compared to tumor-bearing animals treated
with saline. *, p , 0.05 versus saline (Mann-Whitney U-test).
(C) B16-F10 cells were implanted into the striatum of C57/Bl6 mice. 17 d later animals were treated with Ad-Flt3L, Ad-TK (þGCV), Ad-Flt3L plus Ad-TK
(þGCV), or saline. Treatment with Ad-Flt3L and Ad-TK significantly improved survival when compared to saline (*, p , 0.05; Mantel log-rank test), Ad-
Flt3L, or Ad-TK alone treatment groups (^, p , 0.05; Mantel log-rank test). Treatment with Ad-Flt3L, or Ad-TK alone, significantly improved survival
when compared to saline (*, p , 0.05; Mantel log-rank test).
(D) 7 d after treatment, tumor-bearing animals were humanely killed and HMGB1 release was assessed in the serum. Treatment of B16-F10 tumor-
bearing animals with Ad-Flt3L and Ad-TK (þGCV) significantly increased the levels of HMGB1 in the serum when compared to tumor-bearing animals
treated with saline. *, p , 0.05 versus saline (Mann-Whitney U-test).
doi:10.1371/journal.pmed.1000010.g010
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coupled with effective cell killing modalities may be necessary
to achieve therapeutically relevant antitumor efficacy. More-
over, results reported in a Phase I DC vaccine trial for
malignant astrocytoma, highlights the role of chemotherapy
in enhancing DC mediated antitumor immune responses [84].
If endogenous TLR2 signaling is necessary for the
activation of immune responses against tumor antigens by
the immune system, one would expect to see an increased
incidence of cancer correlating with mutations in TLR2.
Genetic evidence recently emerged supporting this hypoth-
esis. SNPs in TLR2 have been correlated with increased
incidence of lymphoma [23] and colorectal cancer [22].
Moreover, several SNP in the TLR6-1-10 gene cluster (TLR2
heterodimeric partners) are associated with the progression
of prostate cancer [24,25]. Thus, the findings reported
underscore the role of tumor-derived TLR2 ligands in
mediating cancer regression in response to anticancer
therapeutics impacting the implementation of brain cancer
immunotherapies in human patients. We believe that the
molecular and cellular mechanisms uncovered herein provide
compelling evidence for the use of immunotherapies in
combination with tumor killing strategies, such as radio-
therapy, chemotherapy, or gene therapy for the effective
treatment and eradication of primary brain gliomas and
metastatic brain tumors. Based on the data reported here,
Ad-TK and Ad-Flt3L have now been chosen for further
downstream process development, manufactured under good
clinical manufacturing processes, and will be tested in early
phase clinical trials for the treatment of resectable, recurrent
glioma in the near future.
Figure 11. Model Illustrating the Role of TLR2 and HMGB1 in Initiating T Cell-Dependent Brain Tumor Regression by Flt3L and TK
Treatment of tumor cells with TK þ GCV releases endogenous TLR2 ligands including HMGB1. DC infiltration into tumors and subsequent activation
require TLR2 signalling. DC phagocytose tumor antigen and migrate to the dLN where they stimulate T cell clonal expansion resulting in T cell-
dependent brain tumor regression and long-term immunological memory.
doi:10.1371/journal.pmed.1000010.g011
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Figure S1. GL26 Cells Do Not Contain Y Chromosomal DNA
Genomic DNA was purified from GL26 tumor cells or from male
C57BL/6 mouse lymphocytes as a positive control using DNeasy
(Qiagen). PCR was used to amplify the male chromosome specific SRY
sequence from 1 ng genomic DNA. GAPDH was also amplified as a
control for DNA loading. GL26 cells do not contain Y chromosomal
DNA and all animals used throughout this study were female to limit
the recognition of proteins expressed at different levels in male mice.
Found at doi:10.1371/journal.pmed.1000010.sg001 (1.3 MB TIF).
Figure S2. Generating GFP Chimeric Mice
(A) WT mice were irradiated and bone marrow from GFPþ/þmice was
transferred into the irradiated WT mice to generate mice with GFPþ/þ
bone marrow-derived immune cells and WT microglia.
(B) GFPþ/þmice were irradiated and bone marrow from WT mice was
transferred into the irradiated GFPþ/þmice to generate chimeric mice
with WT bone marrow-derived immune cells and GFPþ/þ microglia.
As controls, WT bone marrow was transferred into WT mice (GFP
bone marrow-derived leukocytes and microglia) and GFPþ/þ bone
marrow was transferred into GFPþ/þ mice (GFPþ bone marrow-
derived leukocytes and microglia).
Found at doi:10.1371/journal.pmed.1000010.sg002 (1.7 MB TIF).
Figure S3. Development and Characterization of Polycolonal
HMGB1 Antibody
(A) Hopp-Woods and Kyte-Doolittle hydrophobicity plots of mouse
HMGB1 were generated using BioToolKit software. HMGB1-deplet-
ing antibodies were raised in rabbits against the N-terminal sequence
MGKGDPKKPRG.
(B) Anti-HMGB1 antibodies raised in rabbit are immunoreactive for
HMGB1 (;30 kDa) by western blot. Western blot on untreated GL26
cell lysates using Protein G affinity purified, rabbit polyclonal
antibody raised against the N terminus of mouse HMGB1. HMGB1
protein migrated at ;30 kDa.
Found at doi:10.1371/journal.pmed.1000010.sg003 (1.5 MB TIF).
Figure S4. Treatment of GL26 Brain Tumors with Flt3L and TK
Induces T Cell Activation in dLN
We assessed the activation status of T cells in tumor-bearing wt
C57BL/6 mice (black) or TLR2/ mice (red) treated with saline (S),
Ad0 (0), AdFlt3L (F), AdTK (T), or AdFlt3L þ AdTK (F/T) 17 d after
tumor implantation. Animals were killed 7 d later and T cells were
isolated from the dLN. Proliferation of CD4þ T cells (a) and CD8þ T
cells (b) was determined by limited dilution of CFSE using flow
cytometry (*, p , 0.05 versus saline; Kruskal-Wallis followed by
Dunn’s test).
Found at doi:10.1371/journal.pmed.1000010.sg004 (937 KB TIF).
Figure S5. TLR2 Activation by Tumor Extracts
(A) To determine whether components of GL26 cells could stimulate
TLR2 or TLR4 signaling, we cotransfected HEK-293 cells with pGL3-
NFjB (expressing FFLuc) and pTK-rLuciferase (expressing rLuc)
either alone (black, mock), or with pCMV-TLR2 (red, pTLR2), or with
pCMV-TLR4 and pEF1a-MD2 (magenta, pTLR4). After 24 h, cells
were incubated either with GL26 cell extract, PAM3CSK4 (specific
TLR2 ligand), Escherichia coli K12 LPS (specific TLR4 ligand), or
unstimulated control. Renilla and Firefly Luciferase expression was
measured using Dual luciferase kit. NFjB activity was calculated
based on normalized FFLuc reporter activity (FFLuc/rLuc). *, p, 0.05
versus unstimulated controls (Kruskal-Wallis followed by Dunn’s test).
(B) We next determined whether extracts of other tumor cell lines
might also stimulate TLR2 activity. HEK-293 cells were cotransfected
with pGL3-NFjB and pRL-TK either alone (black, mock) or with
pCMV-TLR2 (green, TLR2). After 24 h cells were incubated with
tumor cell extract from GL26 (mouse glioma), LLc1 (mouse lung
carcinoma), CNS1 (rat glioma), or with DSL6A (rat pancreatic
carcinoma). Inset: cells were incubated with 100 ng/ml PAM3
(PAM3CSK4) as a positive control. Normalized FFluc reporter activity
(FFLuc/rLuc) was used to determine NFjB activity (*, p , 0.05 versus
corresponding mock; Mann-Whitney U-test).
Found at doi:10.1371/journal.pmed.1000010.sg005 (2 MB TIF).
Figure S6. AdTK and GCV Induce GL26 Cell Death In Vitro
GL26 cells were mock infected or infected with Ad0, AdTK, or with
AdTK, and media was supplemented with GCV. (A) 3 d later cells
were stained with Annexin-V FITC and cell death was assessed using
flow cytometry (*, p , 0.05 versus saline; Kruskal-Wallis followed by
Dunn’s test).
(B) Dead cells are evident using light microscopy in GL26 cell cultures
treated with Ad-TK þ GCV.
(C) Genomic DNA was isolated from 13 107 GL26 cells infected with
Ad-0, Ad-TK, or Ad-TKþ GCV or mock infected cells 72 h after the
addition of GCV and run on a 2% agarose gel. Only treatment with
AdTK þ GCV resulted in a DNA fragmentation characteristic of
apoptotic cells.
Found at doi:10.1371/journal.pmed.1000010.sg006 (5.3 MB TIF).
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Editors’ Summary
Background. Every year, more than 175,000 people develop a primary
brain tumor (a cancer that starts in the brain rather than spreading in
from elsewhere). Like all cancers, brain tumors develop when a cell
acquires genetic changes that allow it to grow uncontrollably and that
change other aspects of its behavior, including the proteins it makes.
There are many different types of cells in the brain and, as a result, there
are many different types of brain tumors. However, one in five primary
brain tumors is glioblastoma multiforme (GBM; also known as grade 4
astrocytoma), a particularly aggressive cancer. With GBM, the average
time from diagnosis to death is one year and only one person in 20
survives for five years after a diagnosis of GBM. Symptoms of GBM
include headaches, seizures, and changes in memory, mood, or mental
capacity. Treatments for GBM, which include surgery, radiotherapy, and
chemotherapy, do not ‘‘cure’’ the tumor but they can ease these
symptoms.
Why Was This Study Done? Better treatments for GBM are badly
needed, and one avenue that is being explored is immunotherapy—a
treatment in which the immune system is used to fight the cancer.
Because many tumors make unusual proteins, the immune system can
sometimes be encouraged to recognize tumor cells as foreign invaders
and kill them. Unfortunately, attempts to induce a clinically useful anti-
GBM immune response have been unsuccessful, partly because the brain
contains very few dendritic cells, a type of immune system cell that kick-
starts effective immune responses by presenting foreign proteins to
other immune system cells. Another barrier to immunotherapy for GBM
is immune evasion by the tumor. Many tumors develop ways to avoid
the immune response as they grow. For example, they sometimes
reduce the expression of proteins that the immune system might
recognize as foreign. In this study, the researchers test a new combined
treatment strategy for GBM in which dendritic cells are encouraged to
enter the brain and tumor cells are killed to release proteins capable of
stimulating an effective antitumor immune response.
What Did the Researchers Do and Find? The researchers first
established brain tumors in mice. Then, they injected harmless viruses
carrying the genes for Fms-like tyrosine kinase 3 ligand (Ftl3L; a protein
that attracts dendritic cells) and for thymidine kinase (TK; cells expressing
TK are killed by a drug called gancyclovir) into the tumor. Expression of
both Flt3L and TK (but not of either protein alone) plus gancyclovir
treatment shrank the tumors and greatly improved the survival of the
mice. The researchers show that their strategy increased the migration of
dendritic cells into the tumor provided they expressed an immune
system protein called Toll-like receptor 2 (TLR2). TLR2 expression on the
dendritic cells was also needed for an effective anti-tumor immune
response and for tumor regression. TLR2 normally activates dendritic
cells by binding to specific proteins on invading pathogens, so what was
TLR2 binding to in the mouse tumors? The researchers reveal that TLR2
was responding to high-mobility-group box 1 (HMGB1), a protein
released by the dying tumor cells by showing that treatment of the
tumor-bearing mice with the HMGB1 inhibitor glycyrrhizin blocked the
therapeutic effect of Flt3L/TK expression. Finally, the researchers report
that other tumor cell types release HMGB1 when they are killed and that
the Flt3L/TK expression strategy can also kill other tumors growing in
mouse brains.
What Do These Findings Mean? Results obtained in mouse models of
human diseases do not always lead to effective treatments for human
patients. Nevertheless, the findings of this study provide new insights
into how an effective immune response against brain tumors might be
brought about. Most importantly, they show that an effective strategy
might need to both attract dendritic cells into the brain tumor and to kill
tumor cells, so they release proteins that can activate the dendritic cells.
That is, the authors suggest it’s important to combine immunotherapies
with tumor-killing strategies to provide effective treatments for primary
and metastatic brain tumors
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
1000010.
 The US National Cancer Institute provides information about brain
tumors for patients and health professionals and about the the
immune system and how it can be harnessed to fight cancer (in
English and Spanish)
 Cancer Research UK provides information on all aspects of brain
tumors for patients and their caregivers
 MedlinePlus provides links to further information about brain cancer,
(including some links to information in Spanish)
 The American Brain Tumor Association provides brain tumor resources
and information
 The National Brain Tumor Society provides educational and support
services regarding brain tumors
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